RT @MeralElRamahiMD: Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated w
Tweet Content
Post-Hoc of the ASCORE trial showed the following b/l characteristics were most likely associated with remission (per DAS28, SDAI, CDAI) in mod-severe RA patients treated w/ SQ Abatacept:
⭐️Seropositivity
⭐️no prior bMDARD use
⭐️low HAQ-DI
⭐️low BMI
Abst#1228 @ACR21 @Rheumnow https://t.co/LRd1HVbm5B
Show on Archive Page
On
Display in Search Results
On
PDQ
Off